Navigation Links
Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting
Date:10/1/2010

POWAY, Calif., Oct. 1 /PRNewswire/ -- Vet-Stem, Inc. announced that Dr. Robert Harman, DVM, MPVM, CEO of Vet-Stem, will present a talk entitled "Stem Cell Therapy: Mechanisms of Action" at the Annual Research Symposium of the American College of Veterinary Surgeons (ACVS) in Seattle, WA, October 21, 2010.  

(Logo: http://photos.prnewswire.com/prnh/20060425/VETSTEMLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20060425/VETSTEMLOGO)

Dr. Harman has presented at more than 40 veterinary and human stem cell conferences since the founding of Vet-Stem in 2002.  The ACVS is the largest veterinary surgical meeting in the world, with over 7,000 attendees from around the globe.  This seminar talk will provide continuing education for veterinarians on the most current research about how stem cells work to provide healing and improvement in quality of life of animals.

As the founder and scientific director of Vet-Stem, Dr. Harman has been at the forefront of development of the practical applications of stem cells in our animal populations and has consulted with a number of human stem cell companies to share these veterinary findings for the benefit of potential therapy for people.

Vet-Stem's clinical team has rapidly developed this market, training over 4,000 veterinarians in the United States alone and providing stem cells for treatment of over 7,000 horses and dogs.  Peer-reviewed publications in the journals Veterinary Therapeutics and the American Journal of Veterinary Research have demonstrated the effectiveness of these types of treatments in horses and dogs.  In addition, Dr. Harman has co-authored two publications on how these stem cells from fat tissue can help treat multiple sclerosis and autoimmune diseases in people.

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession.  This privately held company delivers stem cell and related services and products to veterinarians to treat diseases in dogs, cats and horses.  These technologies utilize the natural healing properties inherent in all animals to reduce pain and improve the quality of life of our pets.

In January of 2004, Vet-Stem introduced the first veterinary stem cell service in the United States.  Since that time there has been rapid adoption of this technology for treatment of tendon, ligament, and joint injuries by the veterinary community.  Published studies have confirmed that these stem cells can dramatically improve the healing of injuries and diseases that have had very few treatment options in the past.CONTACT INFORMATION:Michael DaleChief Operating Officer, VP Sales & MarketingVet-Stem, Inc.Ph: 858-748-2004 ext 102Fax: 858-748-2005www.vet-stem.com
'/>"/>

SOURCE Vet-Stem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
2. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
3. Syndax Pharmaceuticals to Present at BIO Investor Forum
4. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
5. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
6. Oncothyreon to Present at JMP Securities Healthcare Conference
7. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
8. InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMDs TCT Satellite Symposium in Washington DC., Today.
9. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
10. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
11. Boehringer Ingelheim Presents New Phase III Data Evaluating Linagliptin in People with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... an underwriting agreement with Rodman & Renshaw, a unit ... sole book running manager and representative of several underwriters, under ... firm commitment basis a minimum of 2,105,264 shares of ... purchase a minimum of 1,052,632 shares of common stock ...
(Date:1/23/2017)... -- Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) ... financing, raising $35 million from a syndicate including all Series ... ... Atlas Genetics io® system has been completed with the successful ... February 2016.  This new Series D equity issue will finance ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific ... healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices in ... scientific consultants and contractors. This is the latest step in G&L’s expansion of ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, Inc. ... focused on the licensing, development and commercialization of innovative ... Best Company in North America ... the award based on the FDA approval of ... tablets), ENTYCE ® (capromorelin oral solution) and NOCITA ...
Breaking Biology Technology:
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
Breaking Biology News(10 mins):